Skip to Main Content

Advertisement

Skip Nav Destination

Abstract PR-3: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Mol Cancer Ther (2011) 10 (11_Supplement): PR-3.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal